Spiral Therapeutics, a clinical stage pharmaceutical company focused on the development of first-in-class therapies to target inner ear disorders, has secured $3.7 million as part of a Series A financing round co-led by Savoir Capital and Camden Partners to continue to advance its hearing loss pipeline. Spiral’s lead drug candidate, LPT99, reached the clinic in a Phase 1 study in December 2018.

Since its inception, Spiral has raised over $8.3 million from a diverse base of industry experts, family offices and institutional investors. The company was launched in early 2016 to advance its lead drug candidate, LPT99, with the goal of becoming a leader in the largely underserved inner ear space. The company, headquartered in the San Francisco Bay Area, has an R&D presence in Barcelona, Spain and Baltimore, Maryland via a collaboration with Johns Hopkins University.

Spiral’s executive team includes industry veterans Eugene de Juan and Justin Hanes, and world-renowned neurotologist Charles Limb. Guy Jean Savoir Garcia of Savoir Capital and George Petrocheilos, General Partner at Camden Partners, will join Spiral’s Board of Directors.

“We are delighted to receive this financial support from such experienced life sciences investors, some of whom have been with us since our very early days. Their knowledge and experience will be invaluable as we take important steps in the development of Spiral. This round of financing allows us to take LPT99 into the clinic and further validates our development strategy.” said Hugo Peris, founder and CEO of Spiral Therapeutics.

George Petrocheilos, General Partner at Camden Partners said “Spiral Therapeutics brings together innovative therapies addressing inner ear disorders and a seasoned and energetic management team. Its solid R&D foundation and the meaningful collaborations with leading medical institutions like Johns Hopkins and UCSF make Spiral an ideal investment for Camden. We could not be more excited to be partnering with Hugo Peris and his team.”

About Spiral Therapeutics

Spiral Therapeutics is a clinical stage pharmaceutical company focused on the development of first-in-class therapies to target hearing loss and other inner ear disorders. Through the use proprietary therapeutics and drug delivery technologies, Spiral is building a pipeline of advanced therapies in a field with large unmet needs and no approved therapies. Spiral’s lead candidate, LPT99, reached the clinic in December 2018. Spiral was launched in early 2016 and is headquartered in the San Francisco Bay Area.

For more information, visit www.spiraltx.com